Pancreatic cancer 2

Common Name(s)

Pancreatic cancer 2

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 2" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 2" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 2" returned 156 free, full-text research articles on human participants. First 3 results:

Transcriptional regulation of Δ6-desaturase by peroxisome proliferative-activated receptor δ agonist in human pancreatic cancer cells: role of MEK/ERK1/2 pathway.
 

Author(s): Maryam Darabi, Shima Byagowi, Shabnam Fayezi, Masoud Darabi, Shahab Mirshahvaladi, Mehdi Sahmani

Journal:

 

The Δ6-desaturase (Δ6D), also known as fatty acid desaturase 2, is a regulatory enzyme in de novo fatty acid synthesis, which has been linked to obesity and diabetes. The aim of the present study was to investigate the effect of peroxisome proliferative-activated receptor δ (PPAR ...

Last Updated: 2 Dec 2013

Go To URL
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.
 

Author(s): A H Ko, M A Tempero, Y-S Shan, W-C Su, Y-L Lin, E Dito, A Ong, Y-W Wang, C G Yeh, L-T Chen

Journal: Br. J. Cancer. 2013 Aug;109(4):920-5.

 

PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug. This phase 2 study evaluated PEP02 monotherapy as second-line treatment for pancreatic cancer.

Last Updated: 21 Aug 2013

Go To URL
Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-mediated angiogenesis.
 

Author(s): Li-Hsun Chang, Shiow-Lin Pan, Chin-Yu Lai, An-Chi Tsai, Che-Ming Teng

Journal: Am. J. Pathol.. 2013 Aug;183(2):566-75.

 

Tissue factor initiates the process of thrombosis and activates cell signaling through protease-activated receptor-2 (PAR-2). The aim of this study was to investigate the pathological role of PAR-2 signaling in pancreatic cancer. We first demonstrated that activated PAR-2 up-regulated ...

Last Updated: 26 Jul 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 2" returned 3 free, full-text review articles on human participants. First 3 results:

Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.
 

Author(s): John R Hornick, Dirk Spitzer, Peter Goedegebuure, Robert H Mach, William G Hawkins

Journal: Surgery. 2012 Sep;152(3 Suppl 1):S152-6.

 

One major barrier in the development of pancreas cancer therapeutics is the selective delivery of the drugs to their cellular targets. We have previously developed several sigma-2 ligands and reported the discovery of a component of the receptor for these ligands. Several sigma-2 ...

Last Updated: 21 Aug 2012

Go To URL
Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
 

Author(s): Muhammad Wasif Saif

Journal:

 

Despite attempted curative resection of localized pancreatic adenocarcinoma, most patients succumb a recurrence and die of their disease. The Gastrointestinal Tumor Study Group, European Organization for Research and Treatment of Cancer, and European Study Group for Pancreatic Cancer ...

Last Updated: 7 Jul 2009

Go To URL
Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.
 

Author(s): M Mimeault, S K Batra

Journal: Gut. 2008 Oct;57(10):1456-68.

 

Recent progress on pancreatic stem/progenitor cell research has revealed that the putative multipotent pancreatic stem/progenitor cells and/or more committed beta cell precursors may persist in the pancreatic gland in adult life. The presence of immature pancreatic cells with stem ...

Last Updated: 15 Sep 2008

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2
 

Status: Not yet recruiting

Condition Summary: Locally Advanced Non-metastatic Pancreatic Cancer

 

Last Updated: 7 Apr 2014

Go to URL
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer
 

Status: Recruiting

Condition Summary: Adenocarcinoma of the Pancreas; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer

 

Last Updated: 28 Jul 2014

Go to URL
Pancreatic Cancer Early Detection Program
 

Status: Recruiting

Condition Summary: Pancreatic Cancer; Pancreas Cancer; Pancreatic Adenocarcinoma; Familial Pancreatic Cancer; BRCA 1/2; HNPCC; Lynch Syndrome; Hereditary Pancreatitis; FAMMM; Familial Atypical Multiple Mole Melanoma; Peutz Jeghers Syndrome

 

Last Updated: 30 Jul 2014

Go to URL